Free Trial
OTCMKTS:BIOVF

Swedish Orphan Biovitrum AB (publ) 4/29/2025 Earnings Report

Swedish Orphan Biovitrum AB (publ) logo
$30.29 0.00 (0.00%)
As of 05/27/2025

Swedish Orphan Biovitrum AB (publ) EPS Results

Actual EPS
$0.26
Consensus EPS
$0.22
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

Swedish Orphan Biovitrum AB (publ) Revenue Results

Actual Revenue
$641.33 million
Expected Revenue
$644.12 million
Beat/Miss
Missed by -$2.79 million
YoY Revenue Growth
N/A

Swedish Orphan Biovitrum AB (publ) Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Swedish Orphan Biovitrum AB (publ)'s next earnings date is estimated for Wednesday, July 16, 2025, based on past reporting schedules.

Conference Call Resources

Swedish Orphan Biovitrum AB (publ) Earnings Headlines

Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?
See More Swedish Orphan Biovitrum AB (publ) Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Swedish Orphan Biovitrum AB (publ)? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Swedish Orphan Biovitrum AB (publ) and other key companies, straight to your email.

About Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Sanofi, Apellis Pharmaceuticals Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.

View Swedish Orphan Biovitrum AB (publ) Profile

More Earnings Resources from MarketBeat